Speeding Antibody Screening for Drug Development

Advanced screening technology can dramatically accelerate the hunt for effective treatments for cancer, COVID-19 and more.

Carterra’s LSA platform, which uses the company’s proprietary Epitope software, can sort thousands of antibodies that bind to the same or similar epitopes and group them into families, or bins, of antibodies that share a target. It can also study how rapidly antibodies bind and let go of their target molecules, which reveals both their affinity for a target and their binding kinetics. The LSA also yields information about an antibody’s mechanism of action. Together this information produces a detailed picture of how different antibodies function, which makes it easier to select the most promising candidates from a large library.

Read the Nature Article